tiprankstipranks
Advertisement
Advertisement

SYRE Stock Latest News

Spyre Therapeutics price target raised to $95 from $64 at JonesResearch
The FlySpyre Therapeutics price target raised to $95 from $64 at JonesResearch
11d ago
SYRE
Spyre Therapeutics Raises Capital Through Completed Stock Offering
PremiumCompany Announcements
Spyre Therapeutics Raises Capital Through Completed Stock Offering
11d ago
8K
SYRE
3 Best Trending Stocks, According to Analysts – 4/16/2026
PremiumMarket News
3 Best Trending Stocks, According to Analysts – 4/16/2026
11d ago
AMZN
GSAT
Spyre Therapeutics 6.5M share Secondary priced at $62.00
PremiumThe Fly
Spyre Therapeutics 6.5M share Secondary priced at $62.00
13d ago
SYRE
Spyre Therapeutics price target raised to $90 from $65 at Baird
PremiumThe Fly
Spyre Therapeutics price target raised to $90 from $65 at Baird
14d ago
SYRE
Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo
PremiumThe FlySpyre Therapeutics price target raised to $90 from $50 at Wells Fargo
14d ago
SYRE
Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
Premium
The Fly
Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
14d ago
SYRE
Closing Bell Movers: Bloom Energy spikes on expanded Oracle deal
Premium
The Fly
Closing Bell Movers: Bloom Energy spikes on expanded Oracle deal
14d ago
C
BE
Spyre Therapeutics announces $300M offering of common stock
PremiumThe Fly
Spyre Therapeutics announces $300M offering of common stock
14d ago
SYRE
Spyre Therapeutics Pauses At-The-Market Equity Offering Program
PremiumCompany Announcements
Spyre Therapeutics Pauses At-The-Market Equity Offering Program
14d ago
8K
SYRE
Spyre Therapeutics initiated with a Strong Buy at Raymond James
PremiumThe Fly
Spyre Therapeutics initiated with a Strong Buy at Raymond James
14d ago
SYRE
Buy Rating on SYRE: Early SPY001 Outperformance, Broad IBD Opportunity, and Catalyst‑Rich Path Support Higher $80 Target
PremiumRatings
Buy Rating on SYRE: Early SPY001 Outperformance, Broad IBD Opportunity, and Catalyst‑Rich Path Support Higher $80 Target
14d ago
SYRE
Spyre Therapeutics price target raised to $80 from $65 at Wedbush
PremiumThe FlySpyre Therapeutics price target raised to $80 from $65 at Wedbush
14d ago
TAK
SYRE
Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen
Premium
The Fly
Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen
14d ago
SYRE
Spyre Therapeutics price target raised to $106 from $49 at Leerink
Premium
The Fly
Spyre Therapeutics price target raised to $106 from $49 at Leerink
14d ago
SYRE
Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data
PremiumThe Fly
Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data
14d ago
SYRE
Leerink sees Spyre’s SPY001 Phase 2 Data as incrementally positive for Oruka
PremiumThe Fly
Leerink sees Spyre’s SPY001 Phase 2 Data as incrementally positive for Oruka
14d ago
ORKA
SYRE
Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data
PremiumThe Fly
Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data
14d ago
SYRE
Spyre Therapeutics price target raised to $98 from $70 at BTIG
PremiumThe Fly
Spyre Therapeutics price target raised to $98 from $70 at BTIG
14d ago
SYRE
Spyre Therapeutics price target raised to $85 from $47 at Jefferies
PremiumThe FlySpyre Therapeutics price target raised to $85 from $47 at Jefferies
14d ago
SYRE
Spyre Therapeutics rises 24.2%
Premium
The Fly
Spyre Therapeutics rises 24.2%
14d ago
SYRE
Midday Fly By: Goldman reports Q1 beat, Baker Hughes to sell Waygate
Premium
The Fly
Midday Fly By: Goldman reports Q1 beat, Baker Hughes to sell Waygate
14d ago
GS
BBY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >